Skip to content

Effects of esketamine on perioperative inflammatory cytokines and related complications in patients with one lung ventilation

Effects of Esketamine on the Systemic Inflammatory Response in Thoracic Surgical Patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065915
Enrollment
Unknown
Registered
2022-11-18
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary nodule

Interventions

Experimental group:received esketamine combined with midazolam, propofol, muscle relaxant and dexmedetomidine for anesthesia induction and maintenance
control group:eceived sufentanil, remifentanil combined with midazolam, propofol, muscle relaxant and dexmedetomidine for anesthesia induction and maintenance

Sponsors

Shanghai Changzheng Hospital Anesthesia Department
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients who have a clear preoperative diagnosis and imaging of an occupying lung lesion and are proposed to undergo thoracoscopic lobectomy under general anesthesia and meet the following criteria: 1. Aged 18-65 years, ASA grade I-II, male or female; 2. No preoperative significant organ disease, no cardiopulmonary or hepatic or renal insufficiency, no history of chronic systemic disease, no history of cardiovascular or cerebrovascular disease, no history of psychiatric disease, no history of drug abuse, no history of immune adjuvant therapy, no history of radiotherapy, no history of food and drug allergy; 3. No hormonal and analgesic drugs such as opioids and non-steroidal anti-inflammatory drugs were taken 3 weeks before surgery.

Exclusion criteria

Exclusion criteria: 1. Body mass index > 30 kg/m2; 2. Allergic to the drugs used in this study; 3. Patients with combined cardiopulmonary and hepatic and renal abnormalities, electrolyte disturbances, neuromuscular disorders, severe cardiopulmonary disease, psychiatric disorders, and cognitive impairment; 4. Patients who cannot tolerate one-lung ventilation, patients with a history of rib fracture, ipsilateral lung surgery or history of trauma.

Design outcomes

Primary

MeasureTime frame
interleukin-6;interleukin-8;interleukin-10;

Secondary

MeasureTime frame
General Information;Visual Analogue Scale (VAS) scores;postoperative complications;

Countries

China

Contacts

Public ContactYingke Li

Shanghai Changzheng Hospital

lalalioo@163.com+86 15021188155

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026